Dermata Therapeutics has completed the last patient visit in its pivotal Phase 3 STAR-1 clinical trial of XYNGARI, a novel once-weekly topical treatment for moderate-to-severe acne, with topline results expected by end of March 2025.
Dermata Therapeutics reports steady enrollment progress in its Phase 3 STAR-1 clinical trial for DMT310, a once-weekly topical acne treatment derived from freshwater sponge technology.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.